Bad Homburg – November 03, 2026 -- Fresenius Medical Care narrowed its 2026 operating income outlook to between flat and negative mid-single-digit growth after third-quarter reported operating income fell 19% to EUR 384 million. Reported net income dropped 42%, mainly because of EUR 108 million in one-time costs tied to the company's China strategy refinement.

Bad Homburg, Germany – October 19, 2026 -- Fresenius Medical Care reports that 74% of more than 10,000 high-volume hemodiafiltration (HvHDF) treatments delivered on its 5008X CAREsystem in the United States reached the target convective dose of 23 liters or greater. The company will present the data at the American Society of Nephrology's Kidney Week 2026, held October 21-25 in Denver, Colorado.

Bad Homburg, Germany – September 25, 2026 -- Fresenius Medical Care will exit its peritoneal dialysis business in China and discontinue local production and sales of its 4008A hemodialysis system, triggering one-time costs of approximately €110 million in the third quarter of 2026.

The charge, tied to impairment, scrappage and termination costs, will be treated as a special item and is not expected to meaningfully affect the future revenue outlook for the China business within the Company's Care Enablement segment.